The search for an HIV cure: tackling latent infection (Q38088556)

28 August 2017

title

The search for an HIV cure: tackling latent infection (English)

1 reference

28 August 2017

1 reference

28 August 2017

Jeanette C Reece

0 references

Robert De Rose

0 references

Stephen J Kent

0 references

Miles P Davenport

0 references

Sean Emery

0 references

Janka Petravic

1 reference

28 August 2017

Alexey Martyushev

1 reference

28 August 2017

Anthony D Kelleher

1 reference

28 August 2017

Marit Kramski

1 reference

28 August 2017

David A Cooper

series ordinal

1 reference

28 August 2017

Paul U Cameron

series ordinal

1 reference

28 August 2017

publication date

5 March 2013

1 reference

Lancet Infectious Diseases

28 August 2017

published in

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

614-621

1 reference

HIV reservoirs: pathogenesis and obstacles to viral eradication and cure

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

The challenge of finding a cure for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Interleukin-2 therapy in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

HDAC inhibitors in HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Cell line-dependent variability in HIV activation employing DNMT inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Stability of the latent reservoir for HIV-1 in patients receiving valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Positive results with autologous transplant of ZFN-modified CD4 T-cells: a step toward a practical, functional cure for HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Evaluating therapeutic vaccines in patients infected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Therapeutic immunization in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Therapeutic vaccines against HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Small molecules and big killers: the challenge of eliminating the latent HIV reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

A therapeutic dendritic cell-based vaccine for HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

HIV and SIV CTL escape: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

The utility of ADCC responses in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Activation of NK cells by ADCC antibodies and HIV disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Clinical progression of HIV infection: role of NK cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Analysis of the cytolytic activity mediated by natural killer cells from acquired immunodeficiency syndrome patients in response to phytohemagglutinin or anti-CD16 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

CD56 negative NK cells: origin, function, and role in chronic viral disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

CD4+ count-guided interruption of antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Anti-inflammatory therapy in chronic disease: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

How to escape treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

An "escape clock" for estimating the turnover of SIV DNA in resting CD4⁺ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Compartmentalization of surface envelope glycoprotein of human immunodeficiency virus type 1 during acute and chronic infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

Modelling viral and immune system dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970043-4

7 January 2021

10.1016/S1473-3099(13)70043-4

Identifiers

DOI

1 reference

28 August 2017

1 reference